Selected research
Market Analysis & Forecast
Global Rheumatoid Arthritis Stem Cell Therapy Market Analysis and Forecast 2026-2032
Market perspective
The global Rheumatoid Arthritis Stem Cell Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Rheumatoid Arthritis Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Rheumatoid Arthritis Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Rheumatoid Arthritis Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Rheumatoid Arthritis Stem Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Rheumatoid Arthritis Stem Cell Therapy include International Stem Cell Corporation, Mesoblast, Regeneus, ReNeuron Group, Roslin Cells and Takeda, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Rheumatoid Arthritis Stem Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Rheumatoid Arthritis Stem Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Rheumatoid Arthritis Stem Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Rheumatoid Arthritis Stem Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rheumatoid Arthritis Stem Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rheumatoid Arthritis Stem Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.
Rheumatoid Arthritis Stem Cell Therapy Segment by Company
International Stem Cell Corporation
Mesoblast
Regeneus
ReNeuron Group
Roslin Cells
Takeda
Rheumatoid Arthritis Stem Cell Therapy Segment by Type
Adipose Tissue Stem Cells
Allogeneic Mesenchymal Stem Cells
Bone Marrow Transplant
Rheumatoid Arthritis Stem Cell Therapy Segment by Application
Ambulatory Surgical Centers
Hospitals
Specialty Clinics
Rheumatoid Arthritis Stem Cell Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatoid Arthritis Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rheumatoid Arthritis Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatoid Arthritis Stem Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Rheumatoid Arthritis Stem Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Rheumatoid Arthritis Stem Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rheumatoid Arthritis Stem Cell Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Adipose Tissue Stem Cells
- Allogeneic Mesenchymal Stem Cells
- Bone Marrow Transplant
Applications
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics
Companies covered
- International Stem Cell Corporation
- Mesoblast
- Regeneus
- ReNeuron Group
- Roslin Cells
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Rheumatoid Arthritis Stem Cell Therapy Market by Type
- 1.2.1 Global Rheumatoid Arthritis Stem Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Adipose Tissue Stem Cells
- 1.2.3 Allogeneic Mesenchymal Stem Cells
- 1.2.4 Bone Marrow Transplant
- 1.3 Rheumatoid Arthritis Stem Cell Therapy Market by Application
- 1.3.1 Global Rheumatoid Arthritis Stem Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Ambulatory Surgical Centers
- 1.3.3 Hospitals
- 1.3.4 Specialty Clinics
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Rheumatoid Arthritis Stem Cell Therapy Market Dynamics
- 2.1 Rheumatoid Arthritis Stem Cell Therapy Industry Trends
- 2.2 Rheumatoid Arthritis Stem Cell Therapy Industry Drivers
- 2.3 Rheumatoid Arthritis Stem Cell Therapy Industry Opportunities and Challenges
- 2.4 Rheumatoid Arthritis Stem Cell Therapy Industry Restraints
3 Global Growth Perspective
- 3.1 Global Rheumatoid Arthritis Stem Cell Therapy Market Perspective (2021-2032)
- 3.2 Global Rheumatoid Arthritis Stem Cell Therapy Growth Trends by Region
- 3.2.1 Global Rheumatoid Arthritis Stem Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Rheumatoid Arthritis Stem Cell Therapy Market Size by Region (2021-2026)
- 3.2.3 Global Rheumatoid Arthritis Stem Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Rheumatoid Arthritis Stem Cell Therapy Revenue by Players
- 4.1.1 Global Rheumatoid Arthritis Stem Cell Therapy Revenue by Players (2021-2026)
- 4.1.2 Global Rheumatoid Arthritis Stem Cell Therapy Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Rheumatoid Arthritis Stem Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Rheumatoid Arthritis Stem Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Rheumatoid Arthritis Stem Cell Therapy Key Players Headquarters & Area Served
- 4.4 Global Rheumatoid Arthritis Stem Cell Therapy Players, Product Type & Application
- 4.5 Global Rheumatoid Arthritis Stem Cell Therapy Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Rheumatoid Arthritis Stem Cell Therapy Market CR5 and HHI
- 4.6.3 2025 Rheumatoid Arthritis Stem Cell Therapy Tier 1, Tier 2, and Tier 3
5 Rheumatoid Arthritis Stem Cell Therapy Market Size by Type
- 5.1 Global Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2032)
- 5.3 Global Rheumatoid Arthritis Stem Cell Therapy Revenue Market Share by Type (2021-2032)
6 Rheumatoid Arthritis Stem Cell Therapy Market Size by Application
- 6.1 Global Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2032)
- 6.3 Global Rheumatoid Arthritis Stem Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 International Stem Cell Corporation
- 7.1.1 International Stem Cell Corporation Company Information
- 7.1.2 International Stem Cell Corporation Business Overview
- 7.1.3 International Stem Cell Corporation Rheumatoid Arthritis Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 7.1.4 International Stem Cell Corporation Rheumatoid Arthritis Stem Cell Therapy Product Portfolio
- 7.1.5 International Stem Cell Corporation Recent Developments
- 7.2 Mesoblast
- 7.2.1 Mesoblast Company Information
- 7.2.2 Mesoblast Business Overview
- 7.2.3 Mesoblast Rheumatoid Arthritis Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 7.2.4 Mesoblast Rheumatoid Arthritis Stem Cell Therapy Product Portfolio
- 7.2.5 Mesoblast Recent Developments
- 7.3 Regeneus
- 7.3.1 Regeneus Company Information
- 7.3.2 Regeneus Business Overview
- 7.3.3 Regeneus Rheumatoid Arthritis Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 7.3.4 Regeneus Rheumatoid Arthritis Stem Cell Therapy Product Portfolio
- 7.3.5 Regeneus Recent Developments
- 7.4 ReNeuron Group
- 7.4.1 ReNeuron Group Company Information
- 7.4.2 ReNeuron Group Business Overview
- 7.4.3 ReNeuron Group Rheumatoid Arthritis Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 7.4.4 ReNeuron Group Rheumatoid Arthritis Stem Cell Therapy Product Portfolio
- 7.4.5 ReNeuron Group Recent Developments
- 7.5 Roslin Cells
- 7.5.1 Roslin Cells Company Information
- 7.5.2 Roslin Cells Business Overview
- 7.5.3 Roslin Cells Rheumatoid Arthritis Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 7.5.4 Roslin Cells Rheumatoid Arthritis Stem Cell Therapy Product Portfolio
- 7.5.5 Roslin Cells Recent Developments
- 7.6 Takeda
- 7.6.1 Takeda Company Information
- 7.6.2 Takeda Business Overview
- 7.6.3 Takeda Rheumatoid Arthritis Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 7.6.4 Takeda Rheumatoid Arthritis Stem Cell Therapy Product Portfolio
- 7.6.5 Takeda Recent Developments
8 North America
- 8.1 North America Rheumatoid Arthritis Stem Cell Therapy Revenue (2021-2032)
- 8.2 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2032)
- 8.2.1 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2026)
- 8.2.2 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2027-2032)
- 8.3 North America Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Type (2021-2032)
- 8.4 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2032)
- 8.4.1 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2026)
- 8.4.2 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2027-2032)
- 8.5 North America Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Application (2021-2032)
- 8.6 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Country
- 8.6.1 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021-2026)
- 8.6.3 North America Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue (2021-2032)
- 9.2 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2032)
- 9.2.1 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2026)
- 9.2.2 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2027-2032)
- 9.3 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Type (2021-2032)
- 9.4 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2032)
- 9.4.1 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2026)
- 9.4.2 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2027-2032)
- 9.5 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Application (2021-2032)
- 9.6 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Country
- 9.6.1 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021-2026)
- 9.6.3 Europe Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Rheumatoid Arthritis Stem Cell Therapy Revenue (2021-2032)
- 10.2 China Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2032)
- 10.2.1 China Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2026)
- 10.2.2 China Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2027-2032)
- 10.3 China Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Type (2021-2032)
- 10.4 China Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2032)
- 10.4.1 China Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2026)
- 10.4.2 China Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2027-2032)
- 10.5 China Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue (2021-2032)
- 11.2 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2032)
- 11.2.1 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2026)
- 11.2.2 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2027-2032)
- 11.3 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Type (2021-2032)
- 11.4 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2032)
- 11.4.1 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2026)
- 11.4.2 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2027-2032)
- 11.5 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Application (2021-2032)
- 11.6 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Country
- 11.6.1 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021-2026)
- 11.6.3 Asia Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue (2021-2032)
- 12.2 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2032)
- 12.2.1 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2021-2026)
- 12.2.2 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Type (2027-2032)
- 12.3 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Type (2021-2032)
- 12.4 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2032)
- 12.4.1 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2021-2026)
- 12.4.2 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Application (2027-2032)
- 12.5 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue Share by Application (2021-2032)
- 12.6 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Country
- 12.6.1 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2021-2026)
- 12.6.3 SAMEA Rheumatoid Arthritis Stem Cell Therapy Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst